In a presentation at Clinical Trials at the Summit, Dr. Michael Singer discussed 36-month data from the CALM registry study on Yutiq for chronic noninfectious uveitis. The study included 267 eyes and looked at the impact of Yutiq on uveitis recurrence, OCT visual acuity, visual haze, IOP, and safety. The results showed a substantial reduction in uveitis flares, improved OCT, stable vision, and a consistent IOP profile. Dr. Singer noted that this real-world study builds on previous clinical trials, demonstrating that Yutiq is a relatively safe and effective therapy for uveitis. He also disclosed being a consultant and speaker for Alimera Sciences.
Source link
Yutiq shows positive real-world results in chronic noninfectious uveitis at 3 years
